guselkumab (tremfya) Report issue

Biologics mAb Approved FDA First in Class
AACT ChEMBL DrugBank Drugs@FDA

Active Ingredient History

NOW
  • Now
Guselkumab, sold under the brand name Tremfya, is a monoclonal antibody against interleukin-23 used for the treatment of plaque psoriasis.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$2859.8956

United States

$7942.3100 - $10842.2800
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

cnto 1959 | ctno 1959 | guselkumab | tremfya

Organizations (18)

Research & Development (18)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (14)

Approved Indications (1)


 

Psoriasis

Experimental Indications - Clinical Trial Phases 1-4 (14)


 

Adenomatous Polyposis Coli (Phase 1)

Arthritis, Psoriatic (Phase 4)

Arthritis, Rheumatoid (Phase 2)

Celiac Disease (Phase 1)

Colitis, Ulcerative (Phase 2/Phase 3)

Crohn Disease (Phase 3)

Giant Cell Arteritis (Phase 2)

Healthy Volunteers (Phase 1)

Hidradenitis Suppurativa (Phase 2)

Liver Diseases, Alcoholic (Phase 1)

Lupus Nephritis (Phase 2)

Pityriasis Rubra Pilaris (Phase 2)

Psoriasis ()

Scleroderma, Systemic (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 64
  • # of Trial Organizations: 18

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue